(Press-News.org) New Rochelle, NY, October 16, 2014—To treat the debilitating anemia associated with reduced erythropoietin (EPO) production by the kidneys in chronic renal disease, patients are often given recombinant human EPO to increase hemoglobin levels. But that treatment has risks. A new approach that uses a small interfering RNA (siRNA) drug to stimulate natural EPO production by the liver has shown promising results in nonhuman primates, as reported in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available free on the Nucleic Acid Therapeutics website until November 16, 2014.
Marc T. Abrams and colleagues, Merck Research Laboratories (West Point, PA and Boston, MA), designed a siRNA drug that targets and inhibits expression of the EGLN1 gene, thereby blocking production of a protein called prolyl-4-hydrolase 2 (PHD2). The liver normally makes only small amounts of EPO in adult primates and humans, but one dose of the siRNA drug led to increased levels of EPO and hemoglobin in the blood of the primates. The siRNA effect was dose-dependent and was sustained for at least two months, report the authors in the article "A Single Dose of EGLN1 siRNA Yields Increased Erythropoiesis in Nonhuman Primates."
"The translational relevance of this paper is that it successfully advances the in vivo therapeutic investigation of PHD inhibitors from previous mouse-based work to achieve increased serum EPO and hemoglobin in a primate model, " says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
INFORMATION:
About the Journal
Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website.
About the Society
The Oligonucleotide Therapeutics Society is an open, non-profit forum to foster academia- and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Assay and Drug Development Technologies, Applied In Vitro Toxicology, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Novel RNAi-based therapy for anemia stimulates liver to produce EPO
2014-10-16
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Public health in the 21st century
2014-10-16
Ann Arbor, MI, October 16, 2014 – Although disease outbreaks and epidemics drawing worldwide attention emphasize the importance and acute need for public health professionals, the world faces a longer-term challenge—a public health workforce that is truly effective in the 21st century. In a new supplement to the American Journal of Preventive Medicine, experts address critical challenges to public health, from workforce development, capacity building, partnership and collaborations, and changes and needs in workforce composition.
As the U.S. healthcare system ...
New test can help doctors choose best treatment for ovarian cancer
2014-10-16
Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment.
Successful treatment depends in part on accurately identifying the type of tumour, but this can be difficult. As a result, many women with cancer are not sent to the right specialist surgeon, or those with a benign cyst may have a more serious operation than they need.
In a study published today in the British Medical Journal, an international team led by Imperial College London and KU Leuven, Belgium describe a new test, called ADNEX, which can discriminate ...
Slow and steady does not win the weight loss race
2014-10-16
Led by Joseph Proietto, Sir Edward Dunlop Professor of Medicine at the University of Melbourne and Head of the Weight Control Clinic at Austin Health, the study also found that substantial weight loss is more likely to be achieved if undertaken rapidly.
"This randomised study highlights the urgent need for committees that develop clinical guidelines for the management of obesity to change their advice," he said.
The trial included 200 obese adults (BMI 30–45kg/m²) who were randomly assigned to either a 12-week rapid weight loss programme (average weight ...
Cryptic clues drive new theory of bowel cancer development
2014-10-16
Melbourne researchers have challenged conventional thinking on how the bowel lining develops and, in the process, suggested a new mechanism for how bowel cancer starts.
The researchers produced evidence that stem cells are responsible for maintaining and regenerating the 'crypts' that are a feature of the bowel lining, and believe these stem cells are involved in bowel cancer development, a controversial finding as scientists are still divided on the stem cells' existence.
Using 3D imaging technologies, Dr Chin Wee Tan and Professor Tony Burgess from the Walter and ...
Magnetic mirrors enable new technologies by reflecting light in uncanny ways
2014-10-16
WASHINGTON, Oct. 16—As in Alice's journey through the looking-glass to Wonderland, mirrors in the real world can sometimes behave in surprising and unexpected ways, including a new class of mirror that works like no other.
As reported today in The Optical Society's (OSA) new high-impact journal Optica, scientists have demonstrated, for the first time, a new type of mirror that forgoes a familiar shiny metallic surface and instead reflects infrared light by using an unusual magnetic property of a non-metallic metamaterial.
By placing nanoscale antennas at or ...
Scientists find ancient mountains that fed early life
2014-10-16
VIDEO:
Scientists from Australian National University reveal how they found a mountain range that fed an explosion of life 600 million years ago. The range stretched 2,500 km across Gondwana from...
Click here for more information.
Scientists have found evidence for a huge mountain range that sustained an explosion of life on Earth 600 million years ago.
The mountain range was similar in scale to the Himalayas and spanned at least 2,500 kilometres of modern west Africa and northeast ...
Plant communities produce greater yield than monocultures
2014-10-16
Although monocultures can be cultivated efficiently, they are anything but sustainable: environmental damage to soil and water caused by monoculture cultivation is becoming increasingly evident. Despite their disadvantages, however, monocultures remain the principal crop form and are regarded as the sole possibility of achieving higher yields in plant production – quite wrongfully, finds Bernhard Schmid, an ecology professor at the University of Zurich, who advocates a novel form of agriculture and forestry. After all, a new study carried out by PhD student Debra ...
New perspectives for development of an RSV vaccine
2014-10-16
Respiratory Syncytial Virus causes severe respiratory tract infections and worldwide claims the lives of 160,000 children each year. Scientists at VIB and Ghent University have succeeded in developing a promising vaccination strategy to counteract this common virus infection.
Xavier Saelens (VIB/UGent): "We discovered a new vaccination strategy that paves the way for the development of a novel approach to vaccination against RSV, a virus that causes suffering in numerous small children and elderly people."
RSV: an infection that is difficult to combat
The Respiratory ...
Mild traumatic brain injury can have lasting effects for families, reports the American Journal of Nursing
2014-10-16
October 16, 2014 – Families of patients with mild traumatic brain injury (TBI) may expect them to return to normal quickly—after all, it's "just a concussion." But mild TBI can have a lasting impact on families as well as patients, according to a review in the November issue of American Journal of Nursing. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
"With the increasing numbers of people with mild TBI in the community, it's crucial for nurses to make this a part of assessment for early recognition and intervention," ...
Energy prices and business decision-making in Canada: Preparing for the energy future
2014-10-16
A new expert panel report, Energy Prices and Business Decision-Making in Canada: Preparing for the Energy Future, released today by the Council of Canadian Academies, details how Canadian businesses have historically been successful in responding to fluctuating energy prices, but this should not be considered a predictor for future resiliency or competiveness. The energy environment is evolving with advances in oil and gas extraction, the development of alternative energy sources, changes within the electricity market, and new regulatory requirements. Understanding the ...